This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grundei, T. Articles by Keller, G. Search for Related Content PubMed PubMed Citation Articles by Grundei, T. Articles by Keller, G.

Loss of Heterozygosity and Microsatellite Instability as Predictive Markers for Neoadjuvant Treatment in Gastric Carcinoma¹

Department of Surgery, Klinikum rechts der Isar [T. G., H. V., K. O., J. M., U. F., J. R. S.], Institute of Pathology [K. B., H. H., G. K.], and Institute of Medical Statistics and Epidemiology, Klinikum rechts der Isar [M. S.], Technische Universität München, D-81675 Munich, Germany

We analyzed a group of gastric carcinomas treated with a cisplatin-based neoadjuvant chemotherapy regimen for microsatellite instability (MSI) and loss of heterozygosity (LOH) to determine whether there is any relation between microsatellite alterations and therapy response. Pretherapeutic endoscopic biopsies of 37 patients were studied at 11 microsatellite loci. Thirteen (35%) had a complete or partial clinical response (responders), and 24 (65%) had only a minor or no response (nonresponders). High-grade MSI was found in two tumors, both nonresponders, whereas low-grade MSI was found in five biopsies, including three nonresponders and two responders. Regarding LOH, the most obvious differences between the groups were observed on chromosome 17p13, the location of the p53 gene, with 7 of 12 (58%) and 3 of 20 (15%) of the informative tumors exhibiting LOH in responders and nonresponders, respectively (P = 0.018). A statistically significant difference was also observed in the fractional allelic loss (FAL) ratio of the groups. Among the 13 responding patients, 7 (54%) tumors exhibited high FAL (>0.5–0.75), 2 (15%) showed medium FAL (>0.25–0.5), and 4 (31%) demonstrated low FAL values (0–0.25), whereas among the 22 nonresponding patients, 2 (9%) tumors showed high FAL, 5 (23%) showed medium FAL, and 15 (68%) showed low FAL (P = 0.020).

le;1.5q>These data suggest that LOH at chromosome 17p13 is associated with a good clinical response to cisplatin-based chemotherapy, suggesting that altered p53 function might render cells more sensitive to therapy. Furthermore, the association of FAL with therapy response indicates that gastric carcinomas with a high level of chromosomal alteration may be more sensitive to this type of chemotherapy.

This article has been cited by other articles:

				R. Napieralski, K. Ott, M. Kremer, K. Becker, A.-L. Boulesteix, F. Lordick, J. R. Siewert, H. Hofler, and G. Keller Methylation of Tumor-Related Genes in Neoadjuvant-Treated Gastric Cancer: Relation to Therapy Response and Clinicopathologic and Molecular Features Clin. Cancer Res., September 1, 2007; 13(17): 5095 - 5102. [Abstract] [Full Text] [PDF]

				F Bataille, P Rummele, W Dietmaier, D Gaag, F Klebl, A Reichle, P Wild, F Hofstadter, and A Hartmann Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer Mol. Pathol., October 1, 2003; 56(5): 286 - 292. [Abstract] [Full Text] [PDF]

				K. Ott, H. Vogelsang, J. Mueller, K. Becker, M. Muller, U. Fink, J. R. Siewert, H. Hofler, and G. Keller Chromosomal Instability Rather Than p53 Mutation Is Associated with Response to Neoadjuvant Cisplatin-based Chemotherapy in Gastric Carcinoma Clin. Cancer Res., June 1, 2003; 9(6): 2307 - 2315. [Abstract] [Full Text] [PDF]